Document is current
Any future updates will be listed below
-
Authors
Campesato, Luis Felipe
Budhu, Sadna https://orcid.org/0000-0002-3284-1408
Tchaicha, Jeremy
Weng, Chien-Huan https://orcid.org/0000-0002-5478-9188
Gigoux, Mathieu https://orcid.org/0000-0002-1831-7597
Cohen, Ivan Jose
Redmond, David
Mangarin, Levi
Pourpe, Stephane
Liu, Cailian
Zappasodi, Roberta https://orcid.org/0000-0002-7031-6671
Zamarin, Dmitriy
Cavanaugh, Jill
Castro, Alfredo C.
Manfredi, Mark G.
McGovern, Karen
Merghoub, Taha https://orcid.org/0000-0002-1518-5111
Wolchok, Jedd D. https://orcid.org/0000-0001-6718-2222
-
Funding
Funding for this research was provided by:
Ludwig Institute for Cancer Research
Breast Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 1 August 2019
Accepted: 14 July 2020
First Online: 11 August 2020
Competing interests
: J.T., J.C., A.C., K.M., and M.M. are employed by Ikena Oncology. S.B. is inventor on patent applications related to work on Lag3 and TIM3. R.Z. is inventor on patent applications related to work on GITR, PD-1, and CTLA-4. R.Z. is consultant for Leap Therapeutics. D.Z. reports grants from Merck, and consulting fees from Merck, Synlogic Therapeutics, Trieza Therapeutics, and Tesaro. D.Z. is an inventor on a patent concerning the use of Newcastle Disease Virus for cancer therapy. T.M. is a consultant for Leap Therapeutics, Immunos Therapeutics and Pfizer, and co-founder of Imvaq therapeutics. T.M. has equity in Imvaq therapeutics. T.M. reports grants from Bristol Myers Squibb, Surface Oncology, Ikena Oncology (former Kyn Therapeutics), Infinity Pharmaceuticals, Peregrine Pharmeceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea. T.M. is inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1, and CTLA-4. J.D.W. is a consultant for Adaptive Biotech, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Astellas, Bayer, Beigene, Bristol Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F Star, Genentech, Imvaq, Janssen, Kleo Pharma, Linneaus, MedImmune, Merck Pharmaceuticals, Neon Therapuetics, Ono, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Trieza, Sellas Life Sciences, Serametrix, Surface Oncology, and Syndax. J.D.W. reports grants from Bristol Myers Squibb, Medimmune, Merck Pharmaceuticals and Genentech and honorarium from Esanex. J.D.W. has equity in Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, Beigene, Trieza and Linneaus. J.D.W. is inventor on patent applications related to work on DNA vaccines in companion animals with cancer, assays for suppressive myeloid cells in blood, oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1, and CTLA-4. The remaining authors declare no competing interests.
